RxDoctor Payments Data

Hardik Shah, MD

Family Medicine · Kokomo, INNPI 1326366063

Payments from drug & device makers

$9,955in general payments, 2019–2025

Across 675 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$892
  • Bayer$790
  • GSK$607
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,935100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,955 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$84,571
Medicare patients
291
Services billed
987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin249$268,730
MounjaroTirzepatide106$152,096
OzempicSemaglutide107$140,413
TrulicityDulaglutide61$106,030
JanuviaSitagliptin Phosphate52$83,642
EliquisApixaban84$80,224
RybelsusSemaglutide37$66,008
RexultiBrexpiprazole31$65,377
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$51,657
LinzessLinaclotide37$46,402
MyrbetriqMirabegron54$40,630
AbrysvoRsv Vacc, Pref A And Pref B/Pf112$35,300
XareltoRivaroxaban36$32,348
FarxigaDapagliflozin Propanediol19$31,407
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$26,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$352$281,914277 claims
Lilly USA, LLCMounjaro, Trulicity$892$258,126167 claims
Novo NordiskOzempic, Rybelsus$1,478$206,421144 claims
PfizerEliquis, Abrysvo, Prempro$533$120,730211 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$607$111,189157 claims
MerckJanuvia$184$83,64252 claims
Otsuka America Pharmaceutical, Inc.Rexulti$259$65,37731 claims
AbbVieLinzess$1,022$46,40237 claims
Astellas Pharma US IncMyrbetriq$182$40,63054 claims
Johnson & JohnsonXarelto$44$32,34836 claims
AstraZenecaFarxiga$1,384$31,40719 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$170$20,22517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →